Trial Profile

Immunogenicity and Reactogenicity of Concomitantly Administered Hexavalent and Group B Meningococcal Vaccines in Infancy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib-meningococcal vaccine group C conjugate; Measles mumps and rubella virus vaccine; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group B OMV Novartis; Pneumococcal 13-valent CRM197 vaccine conjugate; RIX 4414
Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
Focus Pharmacodynamics

Most Recent Events

13 Nov 2019 Status changed from Not yet recruiting to Recruiting.
28 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com